WP_Query Object
(
[query] => Array
(
[post_type] => post
[posts_per_page] => 3
[post_status] => publish
[orderby] => rand
)
[query_vars] => Array
(
[post_type] => post
[posts_per_page] => 3
[post_status] => publish
[orderby] => rand
[error] =>
[m] =>
[p] => 0
[post_parent] =>
[subpost] =>
[subpost_id] =>
[attachment] =>
[attachment_id] => 0
[name] =>
[pagename] =>
[page_id] => 0
[second] =>
[minute] =>
[hour] =>
[day] => 0
[monthnum] => 0
[year] => 0
[w] => 0
[category_name] =>
[tag] =>
[cat] =>
[tag_id] =>
[author] =>
[author_name] =>
[feed] =>
[tb] =>
[paged] => 0
[meta_key] =>
[meta_value] =>
[preview] =>
[s] =>
[sentence] =>
[title] =>
[fields] =>
[menu_order] =>
[embed] =>
[category__in] => Array
(
)
[category__not_in] => Array
(
)
[category__and] => Array
(
)
[post__in] => Array
(
)
[post__not_in] => Array
(
)
[post_name__in] => Array
(
)
[tag__in] => Array
(
)
[tag__not_in] => Array
(
)
[tag__and] => Array
(
)
[tag_slug__in] => Array
(
)
[tag_slug__and] => Array
(
)
[post_parent__in] => Array
(
)
[post_parent__not_in] => Array
(
)
[author__in] => Array
(
)
[author__not_in] => Array
(
)
[search_columns] => Array
(
)
[ignore_sticky_posts] =>
[suppress_filters] =>
[cache_results] => 1
[update_post_term_cache] => 1
[update_menu_item_cache] =>
[lazy_load_term_meta] => 1
[update_post_meta_cache] => 1
[nopaging] =>
[comments_per_page] => 50
[no_found_rows] =>
[order] =>
)
[tax_query] => WP_Tax_Query Object
(
[queries] => Array
(
)
[relation] => AND
[table_aliases:protected] => Array
(
)
[queried_terms] => Array
(
)
[primary_table] => wp_posts
[primary_id_column] => ID
)
[meta_query] => WP_Meta_Query Object
(
[queries] => Array
(
)
[relation] =>
[meta_table] =>
[meta_id_column] =>
[primary_table] =>
[primary_id_column] =>
[table_aliases:protected] => Array
(
)
[clauses:protected] => Array
(
)
[has_or_relation:protected] =>
)
[date_query] =>
[request] => SELECT SQL_CALC_FOUND_ROWS wp_posts.ID
FROM wp_posts
WHERE 1=1 AND wp_posts.post_type = 'post' AND ((wp_posts.post_status = 'publish'))
ORDER BY RAND()
LIMIT 0, 3
[posts] => Array
(
[0] => WP_Post Object
(
[ID] => 4488
[post_author] => 4
[post_date] => 2024-10-24 10:45:00
[post_date_gmt] => 2024-10-24 14:45:00
[post_content] =>
Governor Kathy Hochul has unveiled plans for New York BioGenesis Park, a groundbreaking $430 million Cell and Gene Therapy (CGT) Innovation Hub in Nassau County, Long Island. To be developed by The Albanese Organization, Inc., this state-of-the-art facility would catalyze CGT research, development, clinical manufacturing, and commercialization across New York State. With a historic $150 million state investment—the largest nationwide for a cell and gene therapy hub—NYBGP would accelerate the delivery of new therapies from lab to patient in New York's diverse communities. This transformative hub aims to establish New York as the leading global destination for CGT innovation, driving economic growth, attracting top talent, and revolutionizing patient care statewide and beyond.
The Center for Biotechnology is thrilled to be counted as a partner in this effort, and is looking forward to working with our colleagues in the initiative to help catalyze and accelerate life-changing therapies.
New York BioGenesis Park is envisioned as a cutting-edge, full-service campus dedicated to advancing cell and gene therapies and accelerating their commercialization. At full build-out, the 700,000-square-foot park would create an end-to-end Cell and Gene Therapy innovation and supply center, featuring interconnected areas for public engagement, research, manufacturing, and collaboration.
A cornerstone of New York BioGenesis Park is its incubator, supported by a $50 million investment from ESD's Long Island Investment Fund. This facility will empower early-stage therapeutic developers by offering state-of-the-art wet lab space, shared equipment, office space, and other essential resources. This nurturing environment would provide Cell and Gene Therapy companies with access to specialized equipment, mentoring, and stage-appropriate financial guidance. As a critical component of New York BioGenesis Park, the incubator is poised to catalyze the growth of promising Cell and Gene Therapy companies by providing them with resources and support, unlocking their potential for innovation and success.
New York BioGenesis Park would foster strong ties with academic and medical institutions throughout New York, creating a robust ecosystem for Cell and Gene Therapy innovation. Collaborating with the Empire State Cellular Therapy Consortium and world-class institutions like Cold Spring Harbor Laboratory, the Feinstein Institutes, Northwell Health, Roswell Park, Stony Brook University, Weill Cornell, Columbia University and others around the state, New York BioGenesis Park would enhance research synergies and accelerate medical breakthroughs. This ecosystem would bring together experts in advanced Cell and Gene Therapy therapies, offering specialized facilities, services, and resources to both tenants and collaborating institutions. By facilitating cutting-edge science, innovative technology development and novel approaches to clinical trials, New York BioGenesis Park would ensure New York's institutions remain globally competitive in groundbreaking Cell and Gene Therapy research and commercialization.
Read the press release of Governor Hochul's announcement here:
https://www.governor.ny.gov/news/governor-hochul-launches-next-phase-long-islands-nation-leading-cell-and-gene-therapy
[post_title] => Long Island to be location for Nation-Leading Cell and Gene Therapy Innovation Hub: New York BioGenesis Park.
[post_excerpt] =>
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => long-island-to-be-location-for-nation-leading-cell-and-gene-therapy-innovation-hub-new-york-biogenesis-park
[to_ping] =>
[pinged] =>
[post_modified] => 2024-12-05 11:35:07
[post_modified_gmt] => 2024-12-05 16:35:07
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=4488
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[1] => WP_Post Object
(
[ID] => 2364
[post_author] => 4
[post_date] => 2016-08-11 17:51:20
[post_date_gmt] => 2016-08-11 17:51:20
[post_content] => iCell Gene Therapeutics, a CFB client company, has announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for its chimeric antigen receptor engineered T-cells directed against the target protein CD4 (CD4CAR) for the treatment of peripheral T-cell lymphoma (PTCL). The Orphan Drug Designation program provides orphan status, and associated development incentives, to drugs and biologics intended for the safe and effective treatment, diagnosis or prevention of rare diseases or disorders that affect fewer than 200,000 people in the U.S. Read more about the designation and company here.
[post_title] => iCell Gene Therapeutics Granted Orphan Drug Designation
[post_excerpt] => iCell Gene Therapeutics, a CFB client company, has announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for its chimeric antigen receptor engineered T-cells directed against the target protein CD4 (CD4CAR) for the treatment of peripheral T-cell lymphoma (PTCL).
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => icell-gene-therapeutics-granted-orphan-drug-designation
[to_ping] =>
[pinged] =>
[post_modified] => 2017-01-09 15:08:30
[post_modified_gmt] => 2017-01-09 15:08:30
[post_content_filtered] =>
[post_parent] => 0
[guid] => http://centerforbiotechnology.org/?p=2364
[menu_order] => 168
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[2] => WP_Post Object
(
[ID] => 3290
[post_author] => 3
[post_date] => 2019-07-18 19:14:24
[post_date_gmt] => 2019-07-18 19:14:24
[post_content] => Phase 0 Proof-of-Concept Partnership pilot program demonstrates effectiveness for
transitioning basic science discoveries into the commercialization pipeline.
The Long Island Bioscience Hub (LIBH), a National Institutes of Health (NIH) Research Evaluation and Commercialization Hub (REACH), is pleased to announce it has demonstrated significant impact as outlined in a recent evaluative report presenting the results and activities of the NIH REACH program over the pilot period of three years. The LIBH, a collaboration between Stony Brook University, Brookhaven National Laboratory, Cold Spring Harbor Laboratory, and the Feinstein Institute at Northwell Health, led by the Center for Biotechnology, was formed in March 2015 with a mission to help commercialize biomedical technologies emerging from the region’s research institutions.
The report, prepared independently by RTI International on behalf of the NIH, outlines multiple outcomes from the REACH program, and documents the successes that the LIBH has had during the relatively short pilot phase of its work. The LIBH engaged 600 innovators in training sponsored or co-sponsored by the REACH Program. Fifty technology development projects have been funded by LIBH over the course of three years, including technologies focused on biologic drugs, diagnostic devices, small molecule drugs, therapeutic devices, and Health IT among others. As a result of the NIH investment in the LIBH, ten startup companies have been formed and two license agreements have been executed. In addition, the initial investment made by NIH in the region has generated follow on funding of more than $10 million, $2.8 million coming from five funded SBIR/STTR proposals based on LIBH technologies. This impact from the REACH program contributes to the overall economic impact of Center for Biotechnology, notably $1.2B over a recent fifteen year period.
“We are thrilled with the outcomes reported in the RTI evaluation for the Long Island Bioscience Hub’s efforts thus far under the REACH program” said Clinton T. Rubin, Ph.D., Distinguished Professor, Department of Biomedical Engineering, and Director, Center for Biotechnology. “Through the REACH program we’ve been able to expand on the region’s efforts to commercialize more innovation locally, thereby capturing more of the economic impact within the region. While the pilot program will end in mid-2019, these impacts clearly demonstrate the potential of the model to make significant contributions to our innovation ecosystem.”
“The RTI evaluation reinforces our knowledge that the Long Island Bioscience Hub model has already had a significant, positive impact on technologies and innovators embedded in our research community” stated Dr. Richard Reeder, Vice President for Research at Stony Brook University. “It is imperative we continue to fuel the activities of the LIBH as it is an essential part of innovation economy, and is a significant engine in bringing lifesaving technologies to patients.”
The Center for Biotechnology, in collaboration with other partners in the region, will continue to explore how the model might be continued and expanded.
Click here for PDF version.
[post_title] => Long Island Bioscience Hub Reports Significant Impacts
[post_excerpt] => The Long Island Bioscience Hub, is pleased to announce it has demonstrated significant impact as outlined in a recent evaluative report presenting the results and activities of the NIH REACH program over the pilot period of three years.
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => news-libh-impacts
[to_ping] =>
[pinged] =>
https://centerforbiotechnology.org/who-we-are/long-island-bioscience-hub/
[post_modified] => 2019-07-18 19:15:46
[post_modified_gmt] => 2019-07-18 19:15:46
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=3290
[menu_order] => 93
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[3] => WP_Post Object
(
[ID] => 4272
[post_author] => 4
[post_date] => 2023-08-28 13:39:39
[post_date_gmt] => 2023-08-28 17:39:39
[post_content] =>
The Long Island BioMentor Initiative (LIBMI), created and managed by the Center for Biotechnology, is excited to welcome two new mentors, Dr. Annie Rohan, PhD, RN, FAANP, FAAN and Mike Horan, MBA.
Dr. Annie Rohan is currently Dean of the Henry P. Becton School Nursing and Allied Health at Fairleigh Dickinson University. Dr. Rohan is a dual-certified Nurse Practitioner whose academic achievements rest on the foundation of a 25-year clinical career caring for critically and chronically ill infants and children, and highest-risk families. To support diversification of the healthcare workforce, she has procured over $10-million in federal funding to support the education of underrepresented and disadvantaged students into the allied health and nursing professions. Dr. Rohan is currently Associate Editor for MCN: The American Journal of Maternal-Child Nursing, and has been honored with Fellowship in both the American Academy of Nurse Practitioners (FAANP) and American Academy of Nursing (FAAN).
Mike Horan, MBA is a Product Development, Engineering, and Operations Executive. He is an accomplished engineering and technology business leader with over 30 years of experience in product development. At Zebra Technologies, he currently serves as the Sr. Director of Global Quality overseeing quality for their product and solutions portfolio, supply chain and QMS. Mike has experience in Strategic & Portfolio Planning, Engineering Leadership, Program Management, Supply Chain, Manufacturing and Operations —all in a global environment. He is a highly motivational leader with experience in building high-performing teams.
The LIBM brings highly qualified volunteer mentors together with motivated, early-stage bioentrepreneurs to provide actionable guidance and support as they advance their business strategy. The initiative was developed in an alliance with MIT’s successful Venture Mentor Service and employs a team mentoring approach which is guided by a statement of principles to ensure confidentiality and a conflict free environment.
To learn more about the program or get involved, visit the LIBMI website or contact Ashley Abid, LIBMI Operations Manger (ashley.abid@stonybrook.edu)
[post_title] => Long Island BioMentor Initiative Welcomes New Mentors
[post_excerpt] => Dr. Anne Rohan and Mr. Mike Horan have joined the esteem rosters of mentors among the Long Island BioMentor Initiative.
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => new-mentors-libmi-0823
[to_ping] =>
[pinged] =>
[post_modified] => 2024-08-22 11:37:59
[post_modified_gmt] => 2024-08-22 15:37:59
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=4272
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
)
[post_count] => 4
[current_post] => -1
[before_loop] => 1
[in_the_loop] =>
[post] => WP_Post Object
(
[ID] => 4488
[post_author] => 4
[post_date] => 2024-10-24 10:45:00
[post_date_gmt] => 2024-10-24 14:45:00
[post_content] =>
Governor Kathy Hochul has unveiled plans for New York BioGenesis Park, a groundbreaking $430 million Cell and Gene Therapy (CGT) Innovation Hub in Nassau County, Long Island. To be developed by The Albanese Organization, Inc., this state-of-the-art facility would catalyze CGT research, development, clinical manufacturing, and commercialization across New York State. With a historic $150 million state investment—the largest nationwide for a cell and gene therapy hub—NYBGP would accelerate the delivery of new therapies from lab to patient in New York's diverse communities. This transformative hub aims to establish New York as the leading global destination for CGT innovation, driving economic growth, attracting top talent, and revolutionizing patient care statewide and beyond.
The Center for Biotechnology is thrilled to be counted as a partner in this effort, and is looking forward to working with our colleagues in the initiative to help catalyze and accelerate life-changing therapies.
New York BioGenesis Park is envisioned as a cutting-edge, full-service campus dedicated to advancing cell and gene therapies and accelerating their commercialization. At full build-out, the 700,000-square-foot park would create an end-to-end Cell and Gene Therapy innovation and supply center, featuring interconnected areas for public engagement, research, manufacturing, and collaboration.
A cornerstone of New York BioGenesis Park is its incubator, supported by a $50 million investment from ESD's Long Island Investment Fund. This facility will empower early-stage therapeutic developers by offering state-of-the-art wet lab space, shared equipment, office space, and other essential resources. This nurturing environment would provide Cell and Gene Therapy companies with access to specialized equipment, mentoring, and stage-appropriate financial guidance. As a critical component of New York BioGenesis Park, the incubator is poised to catalyze the growth of promising Cell and Gene Therapy companies by providing them with resources and support, unlocking their potential for innovation and success.
New York BioGenesis Park would foster strong ties with academic and medical institutions throughout New York, creating a robust ecosystem for Cell and Gene Therapy innovation. Collaborating with the Empire State Cellular Therapy Consortium and world-class institutions like Cold Spring Harbor Laboratory, the Feinstein Institutes, Northwell Health, Roswell Park, Stony Brook University, Weill Cornell, Columbia University and others around the state, New York BioGenesis Park would enhance research synergies and accelerate medical breakthroughs. This ecosystem would bring together experts in advanced Cell and Gene Therapy therapies, offering specialized facilities, services, and resources to both tenants and collaborating institutions. By facilitating cutting-edge science, innovative technology development and novel approaches to clinical trials, New York BioGenesis Park would ensure New York's institutions remain globally competitive in groundbreaking Cell and Gene Therapy research and commercialization.
Read the press release of Governor Hochul's announcement here:
https://www.governor.ny.gov/news/governor-hochul-launches-next-phase-long-islands-nation-leading-cell-and-gene-therapy
[post_title] => Long Island to be location for Nation-Leading Cell and Gene Therapy Innovation Hub: New York BioGenesis Park.
[post_excerpt] =>
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => long-island-to-be-location-for-nation-leading-cell-and-gene-therapy-innovation-hub-new-york-biogenesis-park
[to_ping] =>
[pinged] =>
[post_modified] => 2024-12-05 11:35:07
[post_modified_gmt] => 2024-12-05 16:35:07
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=4488
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[comment_count] => 0
[current_comment] => -1
[found_posts] => 259
[max_num_pages] => 87
[max_num_comment_pages] => 0
[is_single] =>
[is_preview] =>
[is_page] =>
[is_archive] =>
[is_date] =>
[is_year] =>
[is_month] =>
[is_day] =>
[is_time] =>
[is_author] =>
[is_category] =>
[is_tag] =>
[is_tax] =>
[is_search] =>
[is_feed] =>
[is_comment_feed] =>
[is_trackback] =>
[is_home] => 1
[is_privacy_policy] =>
[is_404] =>
[is_embed] =>
[is_paged] =>
[is_admin] =>
[is_attachment] =>
[is_singular] =>
[is_robots] =>
[is_favicon] =>
[is_posts_page] =>
[is_post_type_archive] =>
[query_vars_hash:WP_Query:private] => 325c4f9f1aebaa5ec90666fa54175ba0
[query_vars_changed:WP_Query:private] =>
[thumbnails_cached] =>
[allow_query_attachment_by_filename:protected] =>
[stopwords:WP_Query:private] =>
[compat_fields:WP_Query:private] => Array
(
[0] => query_vars_hash
[1] => query_vars_changed
)
[compat_methods:WP_Query:private] => Array
(
[0] => init_query_flags
[1] => parse_tax_query
)
)
